Biogen posts more Aduhelm biomarker data and a 'correlation' with Alzheimer's clinical benefit Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck 10 rural states launch lawsuit against CMS' COVID-19 vaccine mandate for healthcare workers Siemens Healthineers, UCSF team up to build carbon-neutral imaging tech Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates Viome passes gut check with $54M haul to grow microbiome-sequencing platform FDA clears heart mapping system that hunts down arrhythmias using only a 12-lead ECG Blue Cross NC teams with Teladoc for expanded telehealth services Carbon Health's new hospital, specialist partner program will help its patients transition to higher acuity care Featured Story | By Angus Liu Biogen has been in hot water lately thanks to the contentious FDA approval of Alzheimer’s disease therapy Aduhelm based on a debatable biomarker. Now, the Big Biotech has turned in data on another biomarker plus an analysis the company says suggests association with a slowing of disease progression. read more |
| |
|---|
|
|
| Seven Keys to Success in Europe For emerging companies seeking to expand into Europe, there are many complexities and potential pitfalls. This 77-page e-book outlines the 7 keys to success when entering Europe for the first time. Download now. |
Top Stories By Nick Paul Taylor The rat-a-tat-tat pace of dealmaking at Merck spinout Organon continues. Having identified more than 140 clinical-phase assets in its wheelhouse, Organon has pulled the trigger on its third deal in six months by agreeing to buy Forendo Pharma for an initial $75 million. read more By Dave Muoio In a complaint filed Nov. 10, states argued that the Biden administration's healthcare worker vaccine requirements will exacerbate the ongoing labor shortage, particularly in rural areas. read more By Andrea Park After medtech peers like Medtronic and BD pledged to work toward net-zero carbon emissions and carbon neutrality in the coming decades, Siemens Healthineers is jumping on the carbon-neutral train. read more By Nick Paul Taylor Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication. read more By Kyle LaHucik Prexasertib has been investigated in nearly 20 clinical studies since being discovered by Array in the 1990's, but Eli Lilly decided to part ways with it in 2019. Now, Acrivon Therapeutics has $100 million in funding to give the drug another shot at potentially treating solid cancers through an equity and licensing agreement with Lilly. read more By Andrea Park With its recently bestowed breakthrough device designation positioning Viome Life Sciences’ mRNA analysis platform firmly in the FDA’s good graces, the gut-testing company has raised $54 million to continue developing the platform. read more By Conor Hale To treat a persistent arrhythmia, surgeons need a map of the cardiac muscle’s electrical activity, a process that takes several, often invasive steps. Vektor Medical's system can help clinicians chart out arrhythmia hotspots noninvasively in 2D and 3D diagrams in less than three minutes. read more By Paige Minemyer Members in most Blue Cross NC's individual and fully insured group plans will be able to access Teladoc Health's virtual platform for acute care and behavioral healthcare needs, the company said. read more By Dave Muoio Through its Carbon Health Connect program, the company will establish technologic and operational integrations with vetted health systems and specialty care providers with the end goal of low-friction patient referrals. The primary care chain has already named John Muir Health as its inaugural partner for the Bay Area. read more |
